Budoprutug Drug Asset Due Diligence Report 2026

This Budoprutug Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Budoprutug can convert its Monoclonal antibody profile and CD19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Budoprutug (query alias: Budoprutug)
Modality / target	Monoclonal antibody; CD19; CD19 inhibitors
Highest global status	Phase 2
Originator	Climb Bio Operating, Inc.
Active developers	Climb Bio, Inc., Beijing Mabworks Biotech Co., Ltd., University of Iowa Pharmaceuticals

The MCP disease footprint includes Idiopathic Membranous Glomerulonephritis, Systemic Lupus Erythematosus, Paraproteinemias. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07564596	Phase 1/2	Recruiting	30	Primary endpoint not disclosed in English source
NCT07096843	Phase 2	Recruiting	45	Primary endpoint not disclosed in English source
NCT07090655	Early Phase 1	Completed	30	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

BUDOPRUTUG, A LOW-FUCOSYLATED ANTI-CD19 MONOCLONAL ANTIBODY, IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INITIAL PHASE 1B STUDY RESULTS

Phase 1/2; n=10; evaluation: Positive. Reported fields: B-cell count(Day 85) = 1.0 cells/μL

A Phase 1b, Single-Arm, Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), in Primary Membranous Nephropathy

Phase 1; n=5; evaluation: Positive. Reported fields: Anti-PRP Antibody Concentrations(anti-PLA2R) = 2 - 18 weeks.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Budoprutug addresses Idiopathic Membranous Glomerulonephritis, Systemic Lupus Erythematosus, Paraproteinemias. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-04-11	Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement	Phase 2	Financial terms not disclosed
2024-01-11	Tenet entered into an asset purchase agreement with Acelyrin, Inc. and WH2, LLC providing for the acquisition of certain assets of Acelyrin related to TNT119	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO